Abstract: The present invention is related to pharmaceutical formulations comprising a synthetic deoxypentitol and methods of use thereof in treating cancer.

Abstract: The present disclosure describes compositions comprising substantially pure ribitol, pharmaceutical compositions of ribitol, and methods of making ribitol. The methods may include combining a reducing agent (e.g., borohydride) and ribose (e.g. D-ribose), optionally with stirring, to form a first reaction mixture; and contacting the first reaction mixture and an acidic quenching agent, optionally with stirring, to form a second reaction mixture, thereby forming ribitol.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: This invention relates to methods and compositions comprising antibodies or fragments thereof comprising a targeting ligand and engineered cytotoxic cells comprising a targeting agent specific for the targeting ligand, for use in inducing cytotoxicity in a cancer cell, in delivering a cytotoxic cell to a cancer cell in a subject, and in treating cancer.

Abstract: In one aspect, devices for image guided laparoscopic surgery are disclosed. Such devices can comprise a shaft, a surgical component, a handle, and one or more sensors. The shaft comprises a proximal end and a terminal end that opposes the proximal end. The surgical component is disposed at the terminal end of the shaft, and the handle extends from the proximal end of the shaft. The handle comprises one or more actuating components configured to actuate the surgical component. The one or more sensors are disposed on or over the handle, and are configured to detect and/or track movement of the handle and/or actuation of one or more of the actuating components.

Abstract: The present disclosure describes a surgical training model that emulates a human pelvis for robotic, laparoscopic, and/or abdominal/open approach surgical training. Methods of performing a simulated surgery using the surgical training model are also provided.

Abstract: The present invention provides methods and compositions for identifying leukemic stem cells.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: The present invention provides methods and compositions involving microbiome signatures and their association with oral complications of cancer therapy.

Abstract: Vascular devices and methods for addressing pathologies in the hemiarch of the aorta are provided. The device includes a main body and a secondary body. The main body has ends that are designed to be connected to corresponding ends of the native blood vessel. The secondary body has a free end and a fixed end that is engaged with an inner surface of the main body. The vascular device is movable from a retracted configuration, in which the secondary body is at least partially contained within the main body and the free end is on a proximal side of the fixed end, to an extended configuration, in which the secondary body is extended distally from the main body and the free end is on a distal side of the fixed end to address defects in the aorta downstream of the hemiarch.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: The present invention provides methods for determining immunomodulatory derivatives (IMiDs) resistance in a subject having a plasma cell disorder.

Abstract: The present invention provides methods for determining the level or status of minimal residue disease (MRD) in a multiple myeloma (MM) patient including analyzing peripheral natural killer (NK), NK-T and T cell distribution and/or activation, and quantifying inflammatory cytokines, chemokines and growth factors in a biological sample obtained from an MM patient to provide a peripheral immune profile; and obtaining a level or status of MRD in the MM patient from the peripheral immune profile, wherein if the peripheral immune profile exceeds a pre-determined threshold, the MM patient is positive for MRD.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: The present invention provides methods and compositions involving genetic markers and their association with oral mucositis occurring in patients who are treated with cancer therapy and/or conditioning therapy for hematopoietic stem cell transplantation.

Abstract: The invention relates to synthetic polynucleotides encoding fukutin related protein (FKRP). The invention further relates to nucleic acid constructs comprising the synthetic polynucleotides and methods of using these synthetic polynucleotides to treat dystroglycanopathy disorders.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.

Abstract: The present invention provides methods and compositions for identifying leukemic stem cells.